Splash
Verona Pharma

Breathtaking Science

Verona Pharma is developing life enhancing treatments for respiratory diseases.
Splash
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function. Clinically relevant secondary endpoints met, including progressive and statistically significant improvements in quality of life. Conference call scheduled for 6.00 am PST / 9.00 am EST / 2.00 pm GMT on Monday, January 13, 2020.

We’re a clinical‑stage biopharmaceutical company focused on developing and commercializing innovative prescription medicines.

We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP ticker.

COPD
The unmet need

COPD

Cystic Fibrosis

Asthma

Chronic Obstructive Pulmonary Disease is a progressive respiratory disease without a cure.

The condition causes loss of lung function, hospitalisations and death. COPD affects approximately 384 million people worldwide and is projected to be the third leading cause of death by 2030, according to the World Health Organization.

Find out more

Latest Film

Verona Pharma can make a real difference to the treatment of COPD, believes CEO Jan-Anders Karlsson

Jan-Anders Karlsson explains that the recent strengthening of the management team has given Verona Pharma the expertise to take its potential respiratory treatment, ensifentrine, to market.

Play

Splash

© Verona Pharma plc 2020. All rights reserved